These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1519 related articles for article (PubMed ID: 25199059)

  • 41. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
    Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
    N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
    Menzies-Gow A; Corren J; Bourdin A; Chupp G; Israel E; Wechsler ME; Brightling CE; Griffiths JM; Hellqvist Å; Bowen K; Kaur P; Almqvist G; Ponnarambil S; Colice G
    N Engl J Med; 2021 May; 384(19):1800-1809. PubMed ID: 33979488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma.
    Oh CK; Leigh R; McLaurin KK; Kim K; Hultquist M; Molfino NA
    Respir Res; 2013 Sep; 14(1):93. PubMed ID: 24050312
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
    Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
    Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
    Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis.
    Canonica GW; Harrison TW; Chanez P; Menzella F; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; Garcia Gil E
    Allergy; 2022 Jan; 77(1):150-161. PubMed ID: 33978983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
    Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
    J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dupilumab in persistent asthma with elevated eosinophil levels.
    Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
    N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience.
    Lim YT; Williams TC; Langley RJ; Weir E
    J Asthma; 2024 Aug; 61(8):793-800. PubMed ID: 38240489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials.
    Liu Y; Zhang S; Li DW; Jiang SJ
    PLoS One; 2013; 8(3):e59872. PubMed ID: 23544105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
    N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.